Marvel Biosciences Corp. (MRVL.V)

CAD 0.16

(10.34%)

Long Term Debt Summary of Marvel Biosciences Corp.

Marvel Biosciences Corp.'s latest annual long term debt in 2023 was 1 Million CAD , down 0.0% from previous year.
Marvel Biosciences Corp.'s latest quarterly long term debt in 2024 Q1 was 1 Million CAD , down 0.0% from previous quarter.
Marvel Biosciences Corp. reported annual long term debt of - CAD in 2022, down 0.0% from previous year.
Marvel Biosciences Corp. reported annual long term debt of - CAD in 2021, down 0.0% from previous year.
Marvel Biosciences Corp. reported quarterly long term debt of 1 Million CAD for 2024 Q1, down 0.0% from previous quarter.
Marvel Biosciences Corp. reported quarterly long term debt of 1.5 Million CAD for 2024 Q2, up 50.0% from previous quarter.

Annual Long Term Debt Chart of Marvel Biosciences Corp. (2023 - 2019)

Historical Annual Long Term Debt of Marvel Biosciences Corp. (2023 - 2019)

Year	Long Term Debt	Long Term Debt Growth
2023	1 Million CAD	0.0%
2022	- CAD	0.0%
2021	- CAD	0.0%
2020	- CAD	0.0%
2019	- CAD	0.0%

Year	Long Term Debt	Long Term Debt Growth
2024 Q3	1.5 Million CAD	0.0%
2024 Q1	1 Million CAD	0.0%
2024 Q2	1.5 Million CAD	50.0%
2023 Q3	848.75 Thousand CAD	0.0%
2023 FY	1 Million CAD	0.0%
2023 Q1	- CAD	0.0%
2023 Q2	- CAD	0.0%
2023 Q4	1 Million CAD	17.82%
2022 Q1	- CAD	0.0%
2022 FY	- CAD	0.0%
2022 Q4	- CAD	0.0%
2022 Q2	- CAD	0.0%
2022 Q3	- CAD	0.0%
2021 Q4	- CAD	0.0%
2021 Q3	- CAD	0.0%
2021 FY	- CAD	0.0%
2020 FY	- CAD	0.0%
2019 FY	- CAD	0.0%

Peer Long Term Debt Comparison of Marvel Biosciences Corp.

Name	Long Term Debt	Long Term Debt Difference
Arch Biopartners Inc.	703.92 Thousand CAD	-42.061%
Covalon Technologies Ltd.	919.08 Thousand CAD	-8.804%
Hemostemix Inc.	4.32 Million CAD	76.86%
Universal Ibogaine Inc.	1.73 Million CAD	42.452%
Kane Biotech Inc.	1.3 Million CAD	23.222%
MedMira Inc.	2.95 Million CAD	66.185%
NervGen Pharma Corp.	105.6 Thousand CAD	-846.934%
XORTX Therapeutics Inc.	- CAD	-Infinity%